ANOxA CORP Completes Initial Studies of its Proprietary EIPH Product

ANOxA CORP, a veterinary research and development company, has completed proof of concept studies of EIPHISOLTM at New Bolton Center, one of the worlds premier equine research facilities at the University Of Pennsylvania School Of Veterinary Medicine.

West Seneca, NY (PRWEB) April 29, 2008-- ANOxA CORP (http://www.anoxacorp.com/), a veterinary research and development company, has completed proof of concept studies of EIPHISOLTM at New Bolton Center, one of the worlds premier equine research facilities at the University Of Pennsylvania School Of Veterinary Medicine. The unique patented treatment has shown significant potential for reducing the severity of Exercised Induced Pulmonary Hemorrhage (EIPH). EIPH is a very common disorder in the equine racing industry and horses afflicted with it are known as bleeders". EIPH has no current FDA approved treatments and represents substantial financial losses for the racing industry and health consequences for equine athletes.

ANOxA President Herman Haenert stated, We are very excited about our patented technology, EIPHISOL, which promises to provide veterinarians with an effective new treatment as well as protecting the health and longevity of the equine athlete. ANOxA Corporation is currently working with the regulatory agencies to ultimately obtain FDA approval for the product."

For additional information on EIPHISOLTM, contact Herman Haenert at hhaenert @ anoxacorp.com or visit www.anoxacorp.com.

EIPHISOL is a trademark of ANOxA Corporation.

ANOxA CORP, headquartered in West Seneca, New York, is a biotechnology company dedicated to Veterinary research applications.

###